Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma

This study looks at whether giving the immunotherapy drug tislelizumab as a shorter infusion (30 minutes) works just as well and is as safe as the standard longer infusion (60 minutes) after surgery for liver cancer. This could make treatment more convenient for patients. **You may be eligible if...** - You are 18 to 75 years old - You have been diagnosed with liver cancer (hepatocellular carcinoma) confirmed by biopsy - Your cancer was at an early to intermediate stage (BCLC stage A-B) and was surgically removed with no spread outside the liver - You have recovered well enough after surgery to start treatment **You may NOT be eligible if...** - You have HIV, active hepatitis B or C infection - You have serious autoimmune disease or other significant health conditions - You have received prior liver cancer treatment or immunotherapy - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.